A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Completed
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: Not set, Memphis, Tennessee +1 locations
Conditions: Multiple Myeloma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.
Gender:
ALL
Ages:
Between 18 months and 29 years
Trial Updated:
02/14/2017
Locations: T.C. Thompson Children's Hospital, Chattanooga, Tennessee +2 locations
Conditions: Leukemia
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/07/2017
Locations: Vanderbilt Cancer Center, Nashville, Tennessee
Conditions: Leukemia
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Completed
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line docetaxel/prednisone treatment alone. This will be a randomized, open-label, multicenter, international trial. Treatment will consist of docetaxel/prednisone/custirsen vs. docetaxel/prednisone. A total of at least 1000 patients will be randomized. Patients will be randomly assigned with... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/13/2016
Locations: Teva Investigational Site 084, Memphis, Tennessee +1 locations
Conditions: Prostate Cancer
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Completed
This is a multicenter, open-label, dose escalation Phase 1 study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2016
Locations: SCRI, Nashville, Tennessee
Conditions: AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/19/2016
Locations: East Tennessee State University Cancer Center at Johnson City Medical Center, Johnson City, Tennessee +2 locations
Conditions: Leukemia
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Completed
This phase I trial studies the side effects and the best dose of temsirolimus when given together with dexamethasone, mitoxantrone hydrochloride, vincristine sulfate, and pegaspargase in treating young patients with relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, mitoxantrone hydrochloride, vincristine sulfate, and pegaspargase... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/09/2015
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Completed
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2014
Locations: Not set, Nashville, Tennessee
Conditions: Liposarcoma, Leiomyosarcoma
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy and kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, bone marrow transplantation, and radiation therapy in treatin... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
07/23/2014
Locations: Vanderbilt Cancer Center, Nashville, Tennessee
Conditions: Leukemia
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
Terminated
RATIONALE: Diphenhydramine, lorazepam, and dexamethasone may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether diphenhydramine, lorazepam, and dexamethasone are more effective than standard therapy in treating nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase II trial is studying diphenhydramine, lorazepam, and dexamethasone to see how well they work compared with standard therapy in treating nausea and vomitin... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
06/26/2014
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Completed
The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/18/2014
Locations: Not set, Chattanooga, Tennessee +1 locations
Conditions: Ovarian Cancer
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Completed
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/27/2014
Locations: Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee
Conditions: Melanoma